DOI: 10.12890/2026_007528

Oxymetazoline-associated refractory atrial fibrillation

Authors

  • Abdelhadi Farouji Department of Internal Medicine, Saint Michael’s Medical Center, New York Medical College, Newark, USA
  • Muhammed Umer Department of Internal Medicine, Saint Michael’s Medical Center, New York Medical College, Newark, USA
  • Arwa Battah Department of Internal Medicine, Saint Michael’s Medical Center, New York Medical College, Newark, USA
  • Masara Touza Department of Internal Medicine, Saint Michael’s Medical Center, New York Medical College, Newark, USA
  • Iyad Farouji Division of Cardiology, Department of Internal Medicine, Saint Michael’s Medical Center, New York Medical College, Newark, USA

abdfarroujeh@hotmail.com

Keywords

Oxymetazoline, atrial fibrillation, nasal decongestants, drug-induced arrhythmia, intensive care unit

Abstract

Introduction: Oxymetazoline is a widely used over-the-counter topical nasal decongestant that is generally perceived as safe. Although systemic cardiovascular adverse effects have been reported, clinically significant arrhythmias remain rare.
Case description: A 64-year-old man with diabetes and hypertension developed new-onset atrial fibrillation with a rapid ventricular response up to 180 bpm. This arrhythmia was refractory to pharmacological and synchronized electrical cardioversion, necessitating intensive care unit admission for refractory arrhythmia and hypoxic respiratory failure. Further history revealed oxymetazoline nasal spray use for several days prior to presentation. Following discontinuation of oxymetazoline, sustained conversion to sinus rhythm occurred and was maintained at 6-month follow-up.
Discussion: This case underscores the potential for serious cardiovascular effects of topical nasal decongestants that may be underrecognized because of their over-the-counter availability. While atrial fibrillation has been reported with other imidazoline-containing nasal decongestants, oxymetazoline-associated atrial fibrillation refractory to standard pharmacologic and electrical cardioversion requiring intensive care unit admission has not been previously reported, to our knowledge.
Conclusion: This case highlights a rare but potentially severe arrhythmogenic complication of oxymetazoline nasal spray. Clinicians should consider over-the-counter topical medications as potential contributors in patients presenting with unexplained or refractory atrial fibrillation.

View the entire article

Downloads

References

  1. Russo E, Giombi F, Paoletti G, et al. Use, abuse, and misuse of nasal medications: real-life survey on community pharmacist’s perceptions. J Pers Med. 2023;13(4):579. doi: 10.3390/jpm13040579.
  2. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, et al. Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x.
  3. Dokuyucu R, Gokce H, Sahan M, Sefil F, Tas ZA, Tutuk O, et al. Systemic side effects of locally used oxymetazoline. Int J Clin Exp Med. 2015;8(2):2674-8.
  4. Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1-e156. doi: 10.1161/CIR.0000000000001193. Erratum in: Circulation. 2024;149(1):e167. doi: 10.1161/CIR.0000000000001207. Erratum in: Circulation. 2024;149(9):e936. doi: 10.1161/CIR.0000000000001218. Erratum in: Circulation. 2024;149(24):e1413. doi: 10.1161/CIR.0000000000001263.
  5. Nesapiragasan V, Hayıroğlu Mİ, Sciacca V, Sommer P, Sohns C, Fink T. Catheter Ablation Approaches for the Treatment of Arrhythmia Recurrence in Patients with a Durable Pulmonary Vein Isolation. Balkan Med J. 2023;40(6):386-394. doi: 10.4274/balkanmedj.galenos.2023.2023-9-48.
  6. Pay L, Tezen O, Çetin T, Yumurtaş AÇ, Keskin K, Dereli Ş, et al. Investigation of predictive parameters for recurrence in patients undergoing electrical cardioversion for atrial fibrillation. J Arrhythm. 2025;41(2):e70053. doi: 10.1002/joa3.70053.
  7. Kalenderoglu K, Hayiroglu MI, Cinar T, Oz M, Bayraktar GA, Cam R, et al. Comparison of inflammatory markers for the prediction of atrial fibrillation recurrence following cryoablation. Biomark Med. 2024;18(17-18):717-725. doi: 10.1080/17520363.2024.2395236.
  8. Glazener F, Blake K, Gradman M. Bradycardia, hypotension, and near-syncope associated with Afrin (oxymetazoline) nasal spray. N Engl J Med. 1983;309(12):731. doi: 10.1056/NEJM198309223091213.
  9. Thrush DN. Cardiac arrest after oxymetazoline nasal spray. J Clin Anesth. 1995;7(6):512-4. doi: 10.1016/0952-8180(95)00060-u.
  10. Khan A, Dewhurst N. Use of sympathomimetic nasal spray in association with cardiac fibroma: an unusual cause of ventricular tachycardia. Br J Clin Pract. 1997;51(3):192-3.
  11. Rajpal S, Morris LA, Akkus NI. Non-ST-elevation myocardial infarction with the use of oxymetazoline nasal spray. Rev Port Cardiol. 2014;33(1):51.e1-4. doi: 10.1016/j.repc.2013.07.011.
  12. Wieneke H. Induction of Atrial Fibrillation by Topical Use of Nasal Decongestants. Mayo Clin Proc. 2016;91(7):977. doi: 10.1016/j.mayocp.2016.04.011.

Published

2026-11-03

Issue

2026: LATEST ONLINE

Categories

How to Cite

1.
Farouji A, Umer M, Battah A, Touza M, Farouji I. Oxymetazoline-associated refractory atrial fibrillation. EJCRIM [Internet]. 2026 Nov. 3 [cited 2026 Nov. 3];13. Available from: https://ejcrim.com/index.php/ejcrim/article/view/7528

Most read articles by the same author(s)